PubMed· 2017· Review
Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment
- 1,249citations
- 2017year
Short summary
Glioblastoma multiforme (GBM) remains largely incurable despite treatment advances, with radiation and genetic syndromes identified as the only risk factors.
AI-generated from the title and abstract; the full text is not read.
Key points
- Glioblastoma multiforme (GBM) is a highly malignant and largely incurable central nervous system tumor.
- The only identified risk factors for GBM are radiation exposure and certain genetic syndromes.
- GBM pathogenesis involves multiple genetic mutations and altered gene expression impacting various signaling pathways.
- Despite multimodal treatment (surgery, chemo-, radiotherapy), the prognosis remains poor, with a median survival of approximately 14 months.
AI-generated from the title and abstract; the full text is not read.
Abstract
Glioblastoma multiforme (GBM) is one of the most malignant types of central nervous system tumors. Despite advances in treatment modalities it remains largely incurable. The objective of our review is to provide a holistic picture of GBM epidemiology, etiology, pathogenesis, clinical findings and treatment. A literature search was conducted for GBM at PubMed and Google Scholar, with relevant key words like glioblastoma multiforme, pathogenesis, signs and symptoms, treatment etc., and papers published until 2015 were reviewed. It was found that radiation and certain genetic syndromes are the only risk factors identified to date for GBM. Depending on the tumor site patients may present to the clinic with varying symptoms. To confirm the presence and the extent of tumor, various invasive and non-invasive imaging techniques require employment. The literature survey revealed the pathogenesis to involve aberrations of multiple signaling pathways through multiple genetic mutations and altered gene expression. Although several treatment options are available, including surgery, along with adjuvant chemo- and radio-therapy, the disease has a poor prognosis and patients generally succumb within 14 months of diagnosis.
The authors' abstract, as published at the source. PubMed, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Genetics (Medicine)
GeneticsMedicine